Clinical Trials Logo

Muscular Dystrophies clinical trials

View clinical trials related to Muscular Dystrophies.

Filter by:

NCT ID: NCT02635321 Completed - Clinical trials for Limb-girdle Muscular Dystrophy

MRI and Muscle Involvement in Patients With Mutations in GMPPB

Start date: November 2015
Phase: N/A
Study type: Observational

Limb girdle muscular dystrophies (LGMD) are a very heterogeneous group of muscle disorders characterized by muscle weakness and atrophy of the proximal muscles of the shoulder and pelvic girdles. LGMD is classified based on its inheritance pattern and genetic cause into more than 31 different types. A new type - type 2T has been found. The genetic cause of type 2T is mutations in Guanosine Diphosphate (GDP)-mannose pyrophosphorylase B (GMPPB). Mutations in GMPPB can also cause Congenital muscular dystrophies (CMD). Only 41 patients with mutations in GMPPB has been reported. In this study, the investigators examine five new cases with the LGMD phenotype. The primary aim is to examine the muscle involvement using MRI.

NCT ID: NCT02625662 Completed - Pediatric Disorder Clinical Trials

Facioscapulohumeral Dystrophy in Children

iFocus
Start date: November 2015
Phase:
Study type: Observational

This study will focus on the symptoms, natural history and clinical impact of facioscapulohumeral muscular dystrophy (FSHD) in children. Symptoms of classical FSHD start in adulthood. However, a small subgroup of FSHD patients have an early, childhood onset. This early onset is associated with faster progression and other symptoms like hearing loss and epilepsy. The symptoms, natural history and clinical impact of FSHD in children are largely unknown. The results of this study will be vital for adequate symptomatic management and trial-readiness.

NCT ID: NCT02603562 Completed - Clinical trials for Facioscapulohumeral Muscular Dystrophy (FSHD)

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy

FSHD
Start date: March 30, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with early onset FSHD.

NCT ID: NCT02579239 Completed - Clinical trials for Facioscapulohumeral Muscular Dystrophy

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)

FSHD
Start date: November 30, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with LGMD2B and FSHD.

NCT ID: NCT02571205 Completed - Clinical trials for Duchenne Muscular Dystrophy

Testosterone Therapy for Pubertal Delay in Duchenne Muscular Dystrophy

Start date: November 2015
Phase:
Study type: Observational

"Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne Muscular Dystrophy" is a single centre observational study that aims to follow the progress of 20 adolescents with Duchenne Muscular Dystrophy (DMD) and delayed puberty who are treated by the Newcastle muscle team, as they are treated with testosterone to induce puberty. The participants will all be treated with the standard stepwise regimen of testosterone injections every 4 weeks and data will be collected to help determine the effectiveness and tolerability of the current treatment regimen. The investigators will use the data to explore the effect of testosterone on pubertal development, growth, muscle strength and function, bone mineral density and body composition and characterise any side effects. Semi-structured interviews will also be carried out to learn the boys' views on the tolerability of the regimen. The study will last up to a maximum of 27 months in total for each participant, but may be less if they are happy with pubertal development before this time. It is important to do this study because from the investigator's limited experience in this group, testosterone treatment seems to be well liked and tolerated but the best treatment regimen to use remains unknown and there is no current consensus. It is not currently part of the standard of care in DMD but it would be important to include it if this study can show that it is an effective treatment for pubertal delay.

NCT ID: NCT02531217 Completed - Clinical trials for Facioscapulohumeral Muscular Dystrophy

Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension

Start date: August 13, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the treatment of adult participants with molecularly defined genetic muscular dystrophies.

NCT ID: NCT02530905 Completed - Clinical trials for Duchenne Muscular Dystrophy

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

Start date: October 8, 2015
Phase: Phase 1
Study type: Interventional

This is a first-in-human dose-titration and open-label extension study to assess safety, tolerability, and pharmacokinetics of SRP-4045 in advanced-stage Duchenne muscular dystrophy (DMD) patients with deletions amenable to exon 45 skipping.

NCT ID: NCT02522507 Completed - Cerebral Palsy Clinical Trials

A Peer E-mentoring Intervention to Improve Employment

Start date: January 2016
Phase: N/A
Study type: Interventional

Despite the strong business case of hiring people with disabilities, a significant proportion of youth with disabilities leave high school and neither work nor continue their education and are unprepared to meet the demands of a work environment. Although youth with disabilities have much to gain from employment readiness programs, they are often excluded from, or have limited access to school and community vocational programs. One encouraging approach to address gaps in vocational programming is through peer mentoring, which may facilitate a smoother transition to adulthood by offering support to enhance coping skills. Despite the increase in online communities, little is known about their impact on vocational mentoring for youth with physical disabilities and their parents. The purpose of this study is to develop, implement and assess the feasibility of an online peer mentor employment readiness intervention for youth with physical disabilities and their parents to improve their self-efficacy, career maturity and social support.

NCT ID: NCT02516085 Completed - Clinical trials for Duchenne Muscular Dystrophy

Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and Metformin

Start date: January 2012
Phase: Phase 1
Study type: Interventional

The purpose of the study is to show that the intake of L-arginine and metformin improves muscle function and delays disease progression in patients with Duchenne's muscular dystrophy.

NCT ID: NCT02485938 Completed - Clinical trials for Duchenne Muscular Dystrophy

HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)

HOPE
Start date: January 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Male subjects with cardiomyopathy secondary to Duchenne muscular dystrophy (DMD) meeting all inclusion and no exclusion criteria will be randomized. All subjects will be at least 12 years of age. They will be randomized in a 1:1 manner to either intracoronary infusion of CAP-1002 in three coronary arteries supplying the three major cardiac territories of the left ventricle of the heart (anterior, lateral, inferior/posterior) or usual care. In the active treatment arm, all three major cardiac territories will be treated (infused) during a single procedure in an open-label fashion.